HLB announced in a regulatory filing that it held a board meeting on the 5th and passed a resolution to issue the 44th unregistered unsecured convertible bonds (CB).

The entire amount of funds raised will be used as operating capital and will be invested sequentially by year into research and development (R&D), clinical trials, and commercialization costs for new drug development. The payment date is August 19, 2026, and the maturity date is August 19, 2029.

This filing comes as market attention is focused on HLB's stock price movement this week. Recently, the stock market has been exhibiting expanding volatility as investor sentiment shifts rapidly depending on domestic and external variables, making it difficult to determine market direction based on short-term fluctuations alone.

Therefore, the trends of the KOSPI and KOSDAQ indices serve as important benchmarks, alongside the movements of individual stocks or specific sectors. If both indices maintain an upward trend, buying interest is likely to spread to individual stocks along with a recovery in investor sentiment. Conversely, if the indices waver, profit-taking sell-offs could quickly emerge, centered on stocks that have posted large gains.

In a highly volatile market, intraday gains may not be sustained or sector rotation may occur rapidly, making it necessary to simultaneously monitor indices, trading volumes, and supply and demand trends.

[※ This article is intended for informational purposes only, and investment decisions and any resulting responsibilities lie solely with the investor. As matters related to specific stocks and companies are highly volatile and fluid, please verify further through the latest regulatory filings and multiple sources before making investment decisions. This is an article partially assisted by AI.]